CardiologysiRNA therapyLipoprotein(a)
Lepodisiran’s Impact on Oxidized Phospholipids in Lipoprotein(a): Advancing Cardiovascular Risk Reduction
By MedXY|Sep 6, 2026
Lepodisiran, an siRNA targeting Lp(a), significantly reduces oxidized phospholipids on apo(a) and apoB, highlighting its therapeutic potential in lowering cardiovascular risk linked to elevated Lp(a).